The isoprostanes: Their quantification as an index of oxidant stress status in vivo

Drug Metabolism Reviews

Volumn 32, Issue 3-4, 2000, Pages 377-385

  Morrow, Jason D ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISOPROSTANE DERIVATIVE;

ALZHEIMER DISEASE; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; CONFERENCE PAPER; DIAGNOSTIC VALUE; HEPATORENAL SYNDROME; HUMAN; LIPID PEROXIDATION; NONHUMAN; OXIDATIVE STRESS; RAT; SCLERODERMA; SMOKING;

ACETAMINOPHEN; ALZHEIMER DISEASE; ANIMALS; DINOPROST; F2-ISOPROSTANES; HEPATORENAL SYNDROME; HUMANS; MODELS, ANIMAL; OXIDATIVE STRESS; SCLERODERMA, SYSTEMIC; SMOKING;

EID: 0034543797     PISSN: 03602532     EISSN: None     Source Type: Journal    
DOI: 10.1081/DMR-100102340     Document Type: Conference Paper

References (27)

1. B. Halliwell and M. Grootveld, The measurement of free radical reactions in humans, FEBS Lett., 213, 9-14 (1987).
2. 2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism, Proc. Natl. Acad. Sci. USA, 87, 9383-9397 (1990).
3. 2-isoprostanes in biological fluids and tissues as measure of oxidant stress, Methods Enzymol., 300, 3-12 (1999).
4. J. D. Morrow, T. M. Harris, and L. J. Roberts, Noncyclooxygenase oxidative formation of a series of novel prostaglandins: Analytical ramifications for measurement of eicosanoids, Anal. Biochem., 184, 1-10 (1990).
5. D. F. Taber, J. D. Morrow, and L. J. Roberts, A nomenclature system for the isoprostanes, Prostaglandins, 53, 63-67 (1997).
6. 2-isoprostanes) are formed in situ on phospholipids, Proc. Natl. Acad. Sci. USA, 89, 10,721-10,725 (1992).
7. J. D. Morrow, Y. Chen, C. J. Brame, J. Yang, S. C. Sanchez, J. Xu, W. E. Zackert, J. A. Awad, and L. J. Roberts, The isoprostanes: Unique prostaglandin-like products of free radical-initiated lipid peroxidation, Drug Metab. Rev., 31, 117-139 (1999).
8. 2α by human platelets, Agents Actions, 45(Suppl.), 27-31 (1995).
9. C. Feillet-Coudray, R. Tourtauchaux, N. Niculescu, E. Rock, I. Tauveron, M. Alexandre-Gouabau, Y. Rayssiguier, I. Jalenques, and A. Mazur, Plasma levels of 8-epi-PGF2α, an in vivo marker of oxidative stress, are not affected by aging or Alzheimer's disease, Free Radical Biol. Med., 27, 463-469 (1999).
10. J. D. Morrow and L. J. Roberts, The isoprostanes: Unique bioactive products of lipid peroxidation, Prog. Lipid Res., 36, 1-21 (1997).
11. 2-isoprostanes) in carbon tetrachloride hepatotoxicity, J. Clin. Invest., 90, 2502-2507 (1992).
12. 2-isoprostanes, J. Nutr., 124, 810-816 (1994).
13. R. F. Burk, K. E. Hill, J. A. Awad, J. D. Morrow, T. Kato, K. A. Cockell, and P. R. Lyons, Pathogenesis of diquat-induced liver necrosis in selenium-deficient rats: Assessment of the roles of lipid peroxidation and selenoprotein P, Hepatology, 21, 561-569 (1995).
14. J. A. Awad, L. J. Roberts, R. F. Burk, and J. D. Morrow, Isoprostanes-prostaglandin-like compounds formed in vivo independently of cyclooxygenase, Gastroenterol. Clin. North Am., 25, 409-427 (1996).
15. J. R. Schelling and S. L. Linas, Hepatorenal syndrome, Semin. Nephrol., 10, 565-570 (1990).
16. 2-isoprostanes) in the hepatorenal syndrome, J. Lipid Med., 6, 417-420 (1993).
17. R. P. Mason and V. Fischer, Free radicals of acetaminophen: Their subsequent reactions and toxicological significance, Fed. Proc., 45, 2493-2499 (1986).
18. D. F. Murrell, A radical proposal for the pathogenesis of scleroderma, J. Am. Acad. Dermatol., 28, 78-85 (1993).
19. C. M. Stein, S. B. Tanner, J. A. Awad, L. J. Roberts, and J. D. Morrow, Evidence of free radical-mediated injury (isoprostane overproduction) in scleroderma, Arthritis Rheum., 39, 1146-1150 (1996).
20. D. F. Church and W. A. Pryor, Free-radical chemistry of cigarette smoke and its toxicological complications, Environ. Health Perspect., 64, 111-126 (1985).
21. 2-isoprostanes) in smokers: Smoking as a cause of oxidative damage, N. Engl. J. Med., 332, 1198-1203 (1995).
22. M. Reilly, N. Delanty, J. A. Lawson, and G. A. FitzGerald, Modulation of oxidant stress in vivo in chronic cigarette smokers, Circulation, 94, 19-25 (1996).
23. L. J. Roberts and J. D. Morrow, Isoprostanes as markers of lipid peroxidation in atherosclerosis, in Molecular and Cellular Basis of Inflammation (C. N. Serhan and P. A. Ward, eds.), Humana Press, Totowa, NJ, 1999, pp. 141-163.
24. W. R. Markesbery, Oxidative stress hypothesis in Alzheimer's disease, Free Radical Biol. Med., 23, 137-147 (1997).
25. 2-isoprostane levels are increased in Alzheimer's disease, Ann. Neurol., 44, 410-413 (1998).
26. T. J. Montine, W. R. Markesbery, W. Zackert, S. C. Sanchez, L. J. Roberts, and J. D. Morrow, The magnitude of brain lipid peroxidation correlates with the extent of degeneration but not with density of neuritic plaques or neurofibrillary tangles or with ApoE genotype in Alzheimer's disease patients, Am. J. Pathol., 155, 863-868 (1999).
27. 2-isoprostanes in probable AD, Ann. Neurol., 52, 562-565 (1999).